Research Article
Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer
Table 1
Association between PRDX expression and OS in GC patients at different clinical stages.
| PRDXs | Clinical stages | Cases | Low | High | HR (95% CI) | value |
| PRDX1 | I | 67 | 34 | 33 | 0.51 (0.17–1.52) | 0.217 | II | 140 | 70 | 70 | 0.80 (0.43–1.46) | 0.462 | III | 315 | 152 | 153 | 0.53 (0.40–0.71) | <0.001 | IV | 148 | 74 | 74 | 0.57 (0.39–0.84) | 0.004 |
| PRDX2 | I | 67 | 34 | 33 | 1.15 (0.43–3.08) | 0.787 | II | 140 | 70 | 70 | 0.79 (0.43–1.44) | 0.439 | III | 315 | 152 | 153 | 0.53 (0.40–0.71) | <0.001 | IV | 148 | 74 | 74 | 0.79 (0.54–1.15) | 0.219 |
| PRDX3 | I | 67 | 34 | 33 | 0.51 (0.17–1.52) | 0.218 | II | 140 | 70 | 70 | 0.79 (0.43–1.44) | 0.749 | III | 315 | 152 | 153 | 0.62 (0.46–0.82) | <0.001 | IV | 148 | 74 | 74 | 0.86 (0.58–1.25) | 0.425 |
| PRDX4 | I | 67 | 34 | 33 | 0.75 (0.28–2.03) | 0.571 | II | 140 | 70 | 70 | 0.94 (0.51–1.72) | 0.836 | III | 315 | 152 | 153 | 0.67 (0.50–0.89) | 0.005 | IV | 148 | 74 | 74 | 0.66 (0.45–0.96) | 0.031 |
| PRDX5 | I | 62 | 31 | 31 | 0.93 (0.31–2.78) | 0.897 | II | 135 | 68 | 67 | 1.41 (0.74–2.68) | 0.294 | III | 197 | 98 | 99 | 1.03 (0.71–1.50) | 0.866 | IV | 140 | 70 | 70 | 0.92 (0.62–1.36) | 0.660 |
| PRDX6 | I | 67 | 34 | 33 | 0.63 (0.23–1.74) | 0.367 | II | 140 | 70 | 70 | 0.92 (0.51–1.67) | 0.787 | III | 315 | 152 | 153 | 0.72 (0.54–0.96) | 0.025 | IV | 148 | 74 | 74 | 0.90 (0.62–1.32) | 0.607 |
|
|